(2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-6-yl)acetamide | 345264-43-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-6-yl)acetamide
• 英文别名: (5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)acetamide；2-(1-azatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraen-3-yl)acetamide
• CAS: 345264-43-9
• 化学式: C₁₃H₁₄N₂O
• 分子量: 214.267
• InChiKey: TVGGUSAEEUFQKP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  48
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-6-yl)acetamide 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 生成 2-(2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-6-yl)ethylamine
  参考文献：
  名称：

  Design, synthesis and melatoninergic activity of new unsubstituted and β,β′-difunctionalised 2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-6-alkanamides

  摘要：

  A series of new 2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-6-alkanamides, with and without alkyl and cycloalkyl moieties in the P-position of the alkanamido side chain, have been prepared and tested for their ability to activate pigment granule aggregation in Xenopus laevis melanophores and bind to the recombinant human MT1 and MT2 melatonin receptor subtypes expressed in NIH 3T3 cells. An increase of the spacer's length in the side chain by a methylene unit (from 17d to 21d) leads to a six-fold decrease in antagonistic activity. On the other hand, the introduction of two methyl groups in the beta-position of the side chain of 17a induces agonist potency (compound 24), implying thus that the two beta-methyl groups are not only tolerated by the receptor, but constitute functional probes in its dynamic agonist-antagonist conformational equilibrium. The presence of more bulky beta-substituents, regardless of the size of the R group, compounds 24a,b, seems to lead to antagonism and to a noteworthy MT2 subtype selectivity. Last, the new N1-C7 annulated derivatives presented herein are substantially more potent than their respective N1-C2 annulated counterparts, previously reported. (c) 2007 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2007.01.005
• 作为产物：
  描述：

  2-(5,6-二氢-4H-吡咯并[3,2,1-IJ]喹啉-1-基)-2-氧代乙酸甲酯 在 palladium on activated charcoal ammonium hydroxide 、 sodium dihydrogenphosphate 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 生成 (2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-6-yl)acetamide
  参考文献：
  名称：

  1,7-Annulated indolocarbazoles as cyclin-dependent kinase inhibitors

  摘要：

  The synthesis and kinase inhibitory activity of a series of novel 1,7-annulated indolocarbazoles 6 and 16 is described. These compounds exhibited potent inhibitory activity against cyclin-dependent kinase 4 and good antiproliferative activity in a human colon carcinoma cell line. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.03.105

文献信息

• [EN] PURINE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DERIVES DE LA PURINE EN TANT QU'INHIBITEURS DE LA KINASE
  申请人：LILLY CO ELI

  公开号：WO2003076442A1

  公开（公告）日：2003-09-18

  The present invention provides kinase inhibitors of Formula I.

  本发明提供了化合物I的激酶抑制剂。
• Agents and methods for the treatment of proliferative diseases
  申请人：——

  公开号：US20030229026A1

  公开（公告）日：2003-12-11

  The present invention provides selective kinase inhibitors of formula (I). 1

  这项发明提供了式（I）的选择性激酶抑制剂。
• Purine derivatives as kinase inhibitors
  申请人：Engler Albert Thomas

  公开号：US20050090483A1

  公开（公告）日：2005-04-28

  The present invention provides kinase inhibitors of Formula I.

  本发明提供了式I的激酶抑制剂。
• Agents and method for the treatment of proliferative diseases
  申请人：——

  公开号：US20030092676A1

  公开（公告）日：2003-05-15

  1 The present invention provides selective kinase inhibitors of formula (I).

  本发明提供了式(I)的选择性激酶抑制剂。
• PURINE DERIVATIVES AS KINASE INHIBITORS
  申请人：Engler Thomas Albert

  公开号：US20090105229A1

  公开（公告）日：2009-04-23

  The present invention provides kinase inhibitors of Formula I.

  本发明提供了化合物I的激酶抑制剂。